ATE243531T1 - Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie - Google Patents

Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie

Info

Publication number
ATE243531T1
ATE243531T1 AT99119057T AT99119057T ATE243531T1 AT E243531 T1 ATE243531 T1 AT E243531T1 AT 99119057 T AT99119057 T AT 99119057T AT 99119057 T AT99119057 T AT 99119057T AT E243531 T1 ATE243531 T1 AT E243531T1
Authority
AT
Austria
Prior art keywords
magnesium
gene
administration
increase
gene therapy
Prior art date
Application number
AT99119057T
Other languages
English (en)
Inventor
Serge Braun
Original Assignee
Transgene Sa
Ass Fr Contre Les Myopathies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa, Ass Fr Contre Les Myopathies filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE243531T1 publication Critical patent/ATE243531T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AT99119057T 1998-09-30 1999-09-30 Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie ATE243531T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98402424A EP0998945A1 (de) 1998-09-30 1998-09-30 Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie

Publications (1)

Publication Number Publication Date
ATE243531T1 true ATE243531T1 (de) 2003-07-15

Family

ID=8235506

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99119057T ATE243531T1 (de) 1998-09-30 1999-09-30 Verwendung von magnesium (mg2+) zur erhöhung der gen-verabreichung bei gentherapie

Country Status (10)

Country Link
US (2) US20020019357A1 (de)
EP (2) EP0998945A1 (de)
JP (1) JP5172054B2 (de)
AT (1) ATE243531T1 (de)
AU (1) AU767294B2 (de)
CA (1) CA2284399C (de)
DE (1) DE69909041T2 (de)
DK (1) DK1004320T3 (de)
ES (1) ES2201611T3 (de)
PT (1) PT1004320E (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278551A2 (de) 2000-04-21 2003-01-29 Vical Incorporated Zusammensetzungen und verfahren zur (in vivo) verabreichung der auf polynukleotiden-basierenden therapeutika
EP1249244A1 (de) * 2001-04-13 2002-10-16 Universiteit Gent Therapeutische Zusammensetzungen zur Behandlung einer g-actin / f-actin-gleichgewicht vermittelten Erkrankung, z.b. einer respiratorischen Erkrankung
EP1270733A1 (de) * 2001-06-21 2003-01-02 Ecole Polytechnique Federale De Lausanne Verfahren zum Einbringen von Nukleinsäure in eukaryotische Zellen
WO2003000908A1 (en) * 2001-06-21 2003-01-03 Ecole Polytechnique Federale De Lausanne A method for introducing a nucleic acid into a eukaryotic cell
JP4499035B2 (ja) * 2003-01-17 2010-07-07 秀樹 大野 遺伝子導入促進剤及びそれを含む遺伝子導入用組成物
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
DE102005007744A1 (de) * 2004-06-24 2006-01-19 Shf Communication Technologies Ag Planetengetriebe zur Kombination unterschiedlicher Energiequellen
GB0817393D0 (en) * 2008-09-23 2008-10-29 Givaudan Sa Flavour
EP2405959A4 (de) * 2009-03-13 2013-10-16 Univ Tufts Verfahren, vorrichtungen und kits zur einführung von genetischem material in lebende zellen
EP3587455A1 (de) 2012-10-23 2020-01-01 Emory University Gm-csf- und il-4-konjugate, zusammensetzungen und zugehörige verfahren
US20210205382A1 (en) * 2018-05-17 2021-07-08 University of Florida Research Foundation, Incorporation Methods and compositions for using metal elements in aav gene therapy
EP3833398A4 (de) 2018-09-21 2021-12-22 University of Connecticut Zusammensetzungen und verfahren zur wiederherstellung der paternalen ube3a-genexpression bei angelman-syndrom beim menschen

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60188069A (ja) * 1984-03-08 1985-09-25 Nakano Vinegar Co Ltd 酢酸菌の環状ｄνａ導入法
US4798789A (en) * 1984-10-05 1989-01-17 Dnax Research Institute Of Molecular And Cellular Biology, Inc. cDNA clones coding for polypeptides exhibiting murine interleukin-2 activity
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2710074B1 (fr) * 1993-09-15 1995-12-08 Rhone Poulenc Rorer Sa Gène GRB3-3, ses variants et leurs utilisations.
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
FR2724665B1 (fr) * 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
JPH08308573A (ja) * 1995-05-19 1996-11-26 Ube Ind Ltd 細胞への遺伝子導入方法及びそれに用いられるウィルス感染培地
WO1997012992A2 (en) 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
US5994316A (en) * 1996-02-21 1999-11-30 The Immune Response Corporation Method of preparing polynucleotide-carrier complexes for delivery to cells
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US5830698A (en) 1997-03-14 1998-11-03 Idec Pharmaceuticals Corporation Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
FR2763958A1 (fr) * 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
EP0996739A2 (de) * 1998-05-06 2000-05-03 Transgene S.A. Verbesserungen der gentherapie durch verwendung der zusammensetzungen die ein polynukleotid und ein nukleasehemmer oder interleukin-10 enthalten

Also Published As

Publication number Publication date
US20020019357A1 (en) 2002-02-14
EP0998945A1 (de) 2000-05-10
JP5172054B2 (ja) 2013-03-27
AU767294B2 (en) 2003-11-06
CA2284399A1 (en) 2000-03-30
EP1004320B1 (de) 2003-06-25
JP2000143549A (ja) 2000-05-23
AU5139799A (en) 2000-04-06
US20020156045A1 (en) 2002-10-24
ES2201611T3 (es) 2004-03-16
EP1004320A1 (de) 2000-05-31
DE69909041T2 (de) 2004-04-01
PT1004320E (pt) 2003-10-31
CA2284399C (en) 2011-01-18
DE69909041D1 (de) 2003-07-31
DK1004320T3 (da) 2003-09-15
US6881724B2 (en) 2005-04-19

Similar Documents

Publication Publication Date Title
ZA937459B (en) Pharmaceutical composition
DE69535576D1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
HUP9801207A2 (hu) Nukleinsavat tartalmazó készítmények, előállításuk és alkalmazásuk
ATE200226T1 (de) Zusammensetzungen die verwendbar sind zur verabreichung von therapeutisch wirksamer polynukleotiden in eine zielzelle und ihre verwendung in gentherapie
DE69909041D1 (de) Verwendung von Magnesium (Mg2+) zur Erhöhung der Gen-Verabreichung bei Gentherapie
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
EP0322319A3 (en) Composition comprising biodegradable ocular implants
AU8039394A (en) Methods for increasing extracellular adenosine and for stabilization mast cells
ATE79544T1 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
ATE197719T1 (de) Verwendung von mesothelialen zellen in der gentherapie
ZA95137B (en) Composition containing nucleic acids preparation and use
CA2346119A1 (en) A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5
IL105219A0 (en) Cyclohexane-ylidene compounds and pharmaceutical compositions containing them
EP1153924A3 (de) Substutuierte 1,3-Oxathiolane mit antiviralen Eigenschaften
ATE90345T1 (de) Bis-naphthalimide, ihre herstellung und verwendung.
EP0151989A3 (en) Means for the treatment of cardiac diseases
WO1997030731A3 (en) Method of preparing polynucleotide-carrier complexes for delivery to cells
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
EP0848948A4 (de) Lang wirksames mittel zur rektalen verabreichung
DE3586281D1 (de) Antisaeurezusammensetzung.
ATE258933T1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
IL95875A0 (en) Illudin analogs,pharmaceutical compositions containing the same and methods for the use thereof
ATE223721T1 (de) Edelfosin zur behandlung von hirntumoren
ZA883744B (en) Promotion of healing of meniscal tissue
DE68924222D1 (de) Megakaryocytopoietin, seine Herstellung und Benutzung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1004320

Country of ref document: EP

EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee